KALEIDO BIOSCI (KLDO)
(Delayed Data from NSDQ)
$14.45 USD
+0.15 (1.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.25 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.45 USD
+0.15 (1.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.25 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y
by Zacks Equity Research
Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.
Editas' (EDIT) Q4 Loss Narrows, Revenues Trump Estimates
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the fourth quarter of 2021 while its revenues beat estimates. Focus remains on the development of lead candidate, EDIT-101.
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.
Kaleido Biosciences, Inc. (KLDO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.
Is a Beat Likely for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Avid (CDMO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.
Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.
Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
by Zacks Equity Research
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 Weeks
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Kaleido Biosciences, Inc. (KLDO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 1.82% and -58.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Down 23.6% in 4 Weeks, Here's Why Kaleido Biosciences, Inc. (KLDO) Looks Ripe for a Turnaround
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.
Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More
by Zacks Equity Research
The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.
Kaleido (KLDO) Reports Positive Results from COVID-19 Study
by Zacks Equity Research
Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.
Kaleido Biosciences (KLDO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Kaleido Biosciences (KLDO) has been struggling lately, but the selling pressure may be coming to an end soon.
New Strong Sell Stocks for November 13th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Is Kaleido Biosciences (KLDO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (KLDO) Outperforming Other Medical Stocks This Year?